Abstract

The use of translational noninvasive neuroimaging has revealed that drug addiction and obesity share striking similarities in functional impairment in discrete brain regions and neurotransmitter circuits. Imaging experiments in both humans and rodents (using complementary experimental designs) show similar abnormalities in brain glucose metabolism in the prefrontal cortex (involved in inhibitory control) and hippocampus (memory) as well as impairments in dopamine signaling in the striatum (involved in food and drug reward, goal orientation, motivation, and habit formation). In both species, many of these observations have been obtained through concurrent and parallel monitoring of both brain activity and behavioral manifestations during drug administration, food sensory (visual, olfactory) stimulation, and craving. This review aims to show that noninvasive brain imaging strategies such as small animal positron emission tomography offer significant potential and promise for modeling motivational disorders such as drug addiction and obesity in humans. Rodent addiction models will prove valuable for understanding brain responses to drug cues and will help guide treatment, especially in relapse situations triggered by exposure to conditioned drug cues.

Key Words: addiction; dopamine; functional magnetic resonance imaging (fMRI); leptin; neuroimaging; obesity; positron emission tomography (PET); rodent model

Introduction

In our approach to the research conducted in our laboratories and reviewed in this article, we consider ingestive behavior a collection of acts that involve introducing something into one’s body, whether by eating, drinking, injecting, smoking, or snorting. We believe it is possible that behaviors associated with seeking or consuming food and drugs of abuse are influenced by similar biochemical and physiological processes.

Disorders such as obesity and drug addiction result from repeated overconsumption of food and drugs and likely originate from disturbances in ingestive behavior (reviewed by Volkow and Wise 2005). The application of such a hypothesis can facilitate the comparison of insights and constructs from obesity and drug addiction research and may thus lead to new discoveries for each disorder. Indeed, there is scientific evidence of biological similarities between drug addiction and obesity (Volkow and Wise 2005). A significant component of such evidence has derived from translational noninvasive neuroimaging experiments in humans and rodents. These studies have shown that in the context of addiction and obesity humans and rodents share similar abnormalities in both brain metabolism in discrete brain areas and brain dopamine (DA1) circuitry. We discuss comparable findings in drug-addicted individuals and rodent models of drug addiction.

This review highlights the translational approach to obesity and drug addiction research by describing imaging modalities and presenting findings related to the application of noninvasive translational neuroimaging in the two types of research in both humans and rodents.

Neurobiology of Ingestive Behavior and Energy Regulation

The involvement of homeostatic mechanisms in ingestive behavioral regulation is well documented. In feeding and energy regulation, such mechanisms include satiety and adiposity signals (Woods and D’Alessio 2008). Satiety signals include ghrelin, cholecystokinin, glucagon-like peptide 1, and gastrin-releasing peptide, among others. These signals are phasic in nature and respond rapidly to regulate the amount of food consumed once feeding has been initiated. They are synthesized and act directly on the brain, and they are also secreted in the periphery.

1Abbreviations that appear ≥3x throughout this article: BOLD, blood oxygen level–dependent; CPP, conditioned place preference; D,R, D2 receptor; DA, dopamine; [18F]FDG, 2-[18F]fluoro-2-deoxy-D-glucose; fMRI, functional magnetic resonance imaging; PET, positron emission tomography
Adiposity signals include insulin and leptin, which enter the brain by active transport and act on specific sites in key brain regions. These signals are characterized by slow (tonic) release and are generally believed to signal insulin for medium- to short-term energy stores (i.e., carbohydrates, glucose) and leptin for long-term energy stores (i.e., fat) for initiating food-seeking behaviors. Release of such phasic and tonic signals is influenced by reward and learning processes that are crucial for survival, such as environmental conditioned stimuli (cues) that have been previously associated with food reinforcement (Narayan et al. 2010).

In drug use, homeostatic mechanisms similarly regulate consumption and initiate drug-seeking behaviors. These mechanisms may be exemplified by features of abuse and addiction such as withdrawal (i.e., drug use is required to correct brain imbalances and return the brain to “normal”) and sensitivity to conditioned drug cues, which are major factors involved in maintenance and relapse behaviors in both active drug users and patients completing rehabilitation programs (Heber and Carpenter 2011; Volkow and Wise 2005; Volkow et al. 2011). As the focus here is on imaging techniques, we refer the reader to more comprehensive reviews (Volkow et al. 2011; Woods and D’Alessio 2008) as well as an article in this issue on the neurobiology of ingestive behavior (Barson et al. 2012).

Similarities Between Obesity and Drug Addiction

Obesity and drug addiction are major societal diseases. Aside from their direct effects on physical health, these disorders may be associated with significant and devastating mental health problems for those afflicted. They can also lead to dysfunctional relations for the affected individual both within the family and with coworkers and other members of society. In addition, sky-rocketing medical costs associated with treatment for drug addiction and obesity (especially for obesity-related complications such as type 2 diabetes and heart disease) affect all members of society. The escalating prevalence of obesity and type 2 diabetes observed in children in recent years is particularly alarming (1 in 3 children born after 2000 is expected to develop type 2 diabetes) (Narayan et al. 2003) and necessitates the use of novel methods to understand and potentially treat this disease. Annual costs related to obesity have been estimated at $147 billion (Finkelstein et al. 2009) and for drug addiction $181 billion (Harwood 2004).

Obesity and drug addiction likely result from disturbances in ingestive behavior (Volkow and Wise 2005). Recent studies have documented the involvement of satiety and adiposity signals in drug addiction; for example, psycho-stimulants (i.e., cocaine and amphetamine) affect circulating levels of ghrelin and leptin (Kobeissy et al. 2008). Accordingly, food restriction indirectly (via its changes in circulating peptide and hormone concentrations) enhances drug seeking (Carr 2007), and ghrelin antagonists attenuate cocaine- and amphetamine-induced locomotor activity and conditioned place preference (CPP) in rats. These behaviors are paralleled by decreases in DA release in the nucleus accumbens (ventral striatum), a brain region heavily implicated in food and drug reward (Jerlhag et al. 2010).

Aside from homeostatic mechanisms, ingestive behavior for both food and drugs of abuse is affected by nonhomeostatic mechanisms that are influenced by taste, pleasure, habits, social interactions, convenience, availability, and stress (Volkow and Wise 2005).

Functional Brain Imaging Techniques in Drug Addiction and Obesity Research

Functional Magnetic Resonance Imaging

**Background**

Functional magnetic resonance imaging (fMRI) offers anatomical and temporal specificity and enables measurement of changes in blood flow in discrete brain areas in response to stimulus presentation. Blood flow responses (ratio of oxygenated to deoxygenated hemoglobin) distort the MRI scanner’s magnetic field, a change that manifests in the contrast at the individual voxel level and is termed the blood oxygen level–dependent (BOLD) signal (Rajagopalan et al. 1995). This contrast is co-registered to a structural brain template, which helps delineate the location of the BOLD signal response. The change in signal is then correlated with the stimulus or event presentation to determine any potential functional involvement of a specific brain region.

**Strengths and Weaknesses**

The use of fMRI is widespread in clinical research because it is entirely noninvasive, the effects of magnetic field exposure do not carry any identified health risks, and it offers excellent anatomical and temporal resolution of brain function in response to disease, complex behavioral tasks, stimuli, or situations. fMRI is based on the principles of neurovascular coupling, and BOLD signal measurements correlate well with neuronal local field potentials in certain brain regions (Ojemann et al. 2010), suggesting that the BOLD signal represents an indirect assessment of neuronal function.

The translational value of fMRI and details regarding its application in rodents have been described elsewhere (Benveniste and Blackband 2006). Imaging awake animals with fMRI has also been reported (Lahti et al. 1998), but this technique requires the use of specialized restraining devices for the animal and may thus require time-consuming stress minimization or training procedures to avoid introducing fear or stress-related experimental confounds to the BOLD signal measures (King et al. 2005).

To our knowledge, fMRI experiments in an animal model of obesity have not been carried out. However, fMRI
experiments focusing on drug addiction (particularly brain activation and concurrent drug administration) have been performed in anesthetized rodents, as described below in the section on Translational Neuroimaging in Drug Addiction Research.

Positron Emission Tomography

Background

Positron emission tomography (PET) is a noninvasive imaging modality that involves administration of positron-emitting radiotracers and subsequent visualization and quantification of the uptake of such tracers in biological tissue over time. PET imaging is a valuable tool for both human and animal medical research because it allows for the monitoring of changes in radiotracer uptake dynamically (in a single imaging session) and longitudinally (across multiple imaging sessions) in the same subject.

As the administered radiotracer decays, it produces positrons, which eventually collide with random electrons and annihilate each other. This annihilation causes the emission of gamma rays, which project at opposite directions (180°) from the point of annihilation. The PET scanner is equipped with gamma ray detectors that are positioned in a ring around the subject. After detecting the gamma ray emissions, the point of annihilation is computed, and sophisticated algorithms are implemented that result in a 2-dimensional image of radiotracer location in the targeted tissue. The radiotracers we focus on in this review are the glucose analogue 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) and the DA D2/D3 receptor antagonist [11C]raclopride.

Strengths and Weaknesses

PET imaging is of high translational value. With the recent development of small animal PET scanners that enable the imaging of rats and mice, brain-disease and brain-behavior associations demonstrated in human studies can be investigated using animal models, in which genetic and environmental factors can be manipulated to uncover cause-effect relationships for specific diseases and behaviors. The findings from such experiments can be translated to human research and contribute to treatment outcomes.

Another strength of PET imaging of laboratory animals is the fact that the same subject can be scanned repeatedly over time with minimal invasiveness (i.e., administration of anesthesia and radiotracer injection) and strong reproducibility (Alexoff et al. 2003). Compared with traditional ex vivo pharmacology experiments, these features make it possible to decrease costs and experimental variability, monitor disease progression, track changes in biological variables in response to treatment, assess drug and gene therapy efficacy, and establish cause-effect relations between brain function and behavior. Furthermore, recent developments in PET instrumentation technology have produced scanners that do not require using anesthesia or immobilizing the subject (Purschke et al. 2005; Schulz et al. 2011). However, these scanners have yet to be thoroughly tested.

Advances in experimental design have partially circumvented the effects of anesthesia on radiotracer uptake. One improvement involves adapting a scanning protocol to include a radiotracer uptake period during which the animal subject is awake (Thanos et al. 2008b) (Figure 1). The major advantage of this approach is that, depending on pharmacokinetic properties of the tracer, it permits the assessment of brain activity, metabolism, and neurotransmitter function in response to stimulus (i.e., conditioned cues) and/or event presentation.

There are some important limitations to this imaging modality, however, the most significant of which is its low temporal resolution. Other limitations include the rate of radiotracer uptake or binding to receptors or enzymes, which must not be too fast (to avoid confounds from cerebral blood flow) or too slow (to avoid limiting its modeling). Another important limitation involves the nonspecific effects of radiotracer uptake (binding to targets other than the primary target; i.e., affinity for nonspecific targets), although these can be controlled by normalizing the measured radiotracer uptake in the desired region against the uptake in a brain area known to not express the desired target. This practice also allows for controlling for differences in metabolic effects of brain radiotracer uptake between subjects. Yet another important consideration is the pharmacological effect of radiotracer administration that can result from occupancy of the targeted receptor or transporter by portions of the radiotracer that are not radioactively labeled during its radiosynthesis.

Finally, depending on the tracer and study objectives, it is important when using PET to monitor certain variables (e.g., blood pressure, heart rate, body weight, and circulating...
Translational Neuroimaging in Drug Addiction Research

Imaging Studies of the Brain in Response to Drugs and Drug Stimuli

Drug Administration

fMRI experiments in drug-addicted human subjects are limited in providing insight into mechanisms involved in drug addiction. Although such studies have highlighted brain activation responses to cocaine (Breiter et al. 1997), heroin (Sell et al. 1999, 2000), and nicotine (Stein et al. 1998), these effects have not been investigated in normal human subjects because of the obvious ethical considerations as well as challenges in subject recruitment, variability (most subjects are polydrug abusers), and controlled substance administration.

Small animal fMRI experiments, on the other hand, offer the advantage of assessing brain activation in response to drug administration in both naïve and drug-exposed subjects, thereby providing deeper insight into the mechanisms that may produce addiction in the first place. This assessment can be done by scanning rodents before and after drug administration, and correlating brain activation before and after drug exposure with an abuse profile (measured via behavioral testing). Such studies have been undertaken, but due to the requirement of motionless scanning using fMRI and the need to scan the subject during the period of drug administration, the experiments have been limited to the pharmacological effects of drugs on the brain in the anesthetized state. The studies have nevertheless provided significant insight into how the brain responds to drugs in naïve or drug-exposed subjects.

One study reported increases in the BOLD signal in the prefrontal and cingulate cortex and decreases in the dorsal and ventral striatum, thalamus, and hypothalamus (Xi et al. 2004) in response to heroin. Interestingly, in that study rats that self-administered heroin showed less of a BOLD signal response than heroin-naïve rats, indicating decreased sensitivity to brain activation (i.e., tolerance) in response to the drug. In the same study, treatment with the γ-aminobutyric acid (GABA) inhibitor gamma-vinyl GABA failed to affect the BOLD signal response to heroin, suggesting that heroin pharmacological brain responses were independent of GABA metabolism. A prior study, however, showed that blocking the mu opioid receptor was successful in altering the BOLD signal response to heroin in rats (Xu et al. 2000).

fMRI studies in rodents have also provided valuable insight into how the brain responds to other drugs. One study reported that cocaine increased brain activation in frontal cortical regions, the dorsal and ventral striatum, and the thalamus (Marota et al. 2000). A major advantage of the specific imaging technique used in that study was that the authors reported differential temporal brain responses among the activated brain regions. This feature of fMRI is unique in that it offers high temporal resolution. Finally, D1 receptor (D1R) antagonism was able to block the cocaine-induced brain responses.

Thus, incorporating a pharmacological challenge allows investigators to make generalizations to specific neurotransmitter systems and mechanisms. fMRI studies in rodents offer significant promise for modeling human drug use and its pharmacological treatment. Future studies assessing behavioral interventions coupled with imaging will shed additional light in this area.

As an alternative to fMRI, microPET (µPET) has been used to study the pharmacological effects of a drug on brain activity by measuring brain glucose metabolism (using FDG as radiotracer) while the animal is awake and unrestrained.

Recent µPET studies reported changes in vivo brain activity in mice after acute psychostimulant administration (Michaelides et al. 2010; Thanos et al. 2008a). The animals stayed awake and unrestrained during the FDG uptake period and were anesthetized 5 minutes before the PET scan (Figure 1). One study showed that an intraperitoneal dose of 10 mg/kg of cocaine decreased glucose metabolism in discrete brain regions (olfactory bulb, motor cortex, striatum, hippocampus, thalamus, and cerebellum) in wild-type mice but not (except in the thalamus) in mice that lacked the dopamine transporter (Thanos et al. 2008a). These results suggest that the acute pharmacological effects of cocaine on the brain are mediated primarily by dopaminergic mechanisms but that thalamic noradrenergic and serotonergic mechanisms are also involved.

Another study using a similar imaging procedure reported that an acute intraperitoneal 10 mg/kg dose of methylphenidate increased brain metabolism in the cerebellum and decreased it in the left and right prefrontal cortices in wild-type mice, but had the opposite effects in mice lacking D1 receptors. This result implies the potential regulation of methylphenidate pharmacological activity via the D1R in these brain regions (Michaelides et al. 2010).

These studies offer insight into the use of small animal functional neuroimaging techniques to assess acute and long-term pharmacological effects of addictive substance administration. The development of genetically engineered models that mimic genetic abnormalities similar to those observed in clinical experiments makes such approaches even more advantageous.

Drug Cues

fMRI studies of pharmacological effects on human brain activity have shed light on the brain mechanisms involved in...
the perception of conditioned drug cues while providing testable hypotheses on potential treatments (Goldstein et al. 2007, 2009a,b; Tomasi et al. 2007; Volkow et al. 2006, 2010b). Exposing subjects to cues previously associated with drug abuse is not subject to the same regulatory constraints as pharmacological administration and therefore presents a feasible alternative to drug addiction studies in non-drug-abusing populations. We do not, however, discuss human fMRI findings here because no translational studies currently use these techniques.

In rodents, fMRI experiments that involve exposure to a cue require the subject to be awake, a state that has not yet been reported. As mentioned above, devices that allow for awake fMRI imaging do exist, but their application to drug addiction research has not been assessed.

Brain Imaging Studies of Dopamine in Drug Addiction Research

Drug Administration

Investigators who have used PET in human imaging experiments have documented that acute administration of stimulant drugs of abuse such as amphetamine, methylphenidate, nicotine, and alcohol leads to increases in DA in reward/motivation-associated brain regions (i.e., striatum) and that the magnitude of these changes is linked to the subjective experience of being “high” (Volkow et al. 2010a). PET imaging studies in humans have also shown that long-term drug exposure leads to decreases in DA release in the striatum as well as decreased sensitivity to reinforcing and dopaminergic effects (Volkow et al. 2010a) in response to drug administration in addicted individuals.

Rodent µPET studies on the DA system have documented changes in D1 and D2 receptor availability in response to chronic cocaine exposure (Tsukada et al. 1996) and cocaine withdrawal (Maggos et al. 1998). In particular, withdrawal from cocaine for 10 days increased D1R binding availability to normal (precocaine) levels, but produced a further decline in D2R binding availability (Maggos et al. 1998). Interestingly, D1R binding levels returned to normal precocaine levels by the 21st day of withdrawal, indicating that D1 and D2 receptors exhibit different plasticity in response to withdrawal from cocaine.

Our group conducted a µPET study in rats showing that 2 months of oral methylphenidate administration decreased D1R binding availability, whereas 8 months increased it (Thanos et al. 2007). Interestingly, the animals that showed the increased binding after 8 months also self-administered less cocaine (Thanos et al. 2007). Although a clear advantage of using µPET in this study was that we were able to scan the same animals after 2 and 8 months of methylphenidate treatment, we were not able to assess the effect of 2-month methylphenidate treatment on cocaine self-administration to confirm that the decreased D1R was associated with increased cocaine self-administration.

Human PET imaging studies have shown that discrete cues associated with cocaine abuse (observed in a video of subjects smoking cocaine) elicited increases in striatal DA in cocaine addicts and that the magnitude of increase was positively correlated with reports of drug craving and addiction severity scores (Volkow et al. 2006, 2010a) (Figure 2). Similar findings have been observed in rat models of cocaine abuse in which µPET and the CPP paradigm were used jointly to assess the relation between changes in brain DA and behavioral preference for a conditioned contextual cue associated with cocaine administration (i.e., the cocaine-paired chamber) (Schiffer et al. 2009) (Figure 2). In this study, rats were exposed to a CPP procedure and, after being conditioned to associate the effects of cocaine with a contextual environment, injected with radiolabeled [11C]raclopride and exposed to both the vehicle and the cocaine-paired conditioning environment on two separate occasions. Like the human experiments, this study showed that exposure to drug cues leads to DA increases in the ventral striatum and that the magnitude of increase correlates with cocaine CPP (Schiffer et al. 2009).

Translational Neuroimaging in Obesity Research

Brain Activation in Response to Food and Food Cues

Obesity and Sensory Processing

The human brain is highly sensitive to food stimuli, probably because food is essential for survival. Brain imaging studies have shown that food presentation leads to large and significant increases in brain metabolism (Wang et al. 2004).

Using PET and [18F]FDG, we showed that, when presented with food, subjects exhibited significant increases in brain metabolism in the superior temporal, anterior insula, and orbitofrontal cortices. Increases in the latter, in particular, positively correlated with ratings of hunger and desire for consuming the food (Wang et al. 2004). Using a similar imaging approach, we showed that obese (relative to lean) individuals at baseline condition (i.e., without food presentation) exhibit greater brain metabolism in brain areas associated with sensory processing (Wang et al. 2002). We speculated that this enhanced level of brain metabolism may render obese individuals sensitive to hedonic and reward-related features of food via exteroceptive stimulation and thus contribute to overeating.

Obesity may also be associated with impaired sensory sensitivity to interoceptive (as well as exteroceptive) stimuli. Findings from our group support the notion that interoceptive signals relating to postigestive food effects may be involved in regulating food-related satiety and reward.
Using [18F]FDG and PET in obese humans, we evaluated the effects on brain metabolism of an implantable gastric stimulator (IGS), a device used for clinical obesity management that operates by electrically stimulating the enteric nervous system and disrupting gastric motility (this motility stimulates feelings of hunger) (Chen 2004). IGS is effective in decreasing food consumption, blood pressure, and body weight in obese humans (Cigaina 2004), and we therefore hypothesized that its therapeutic efficacy involves modulation of food satiety signals (i.e., similar to postprandial signals to the brain originating from the vagus nerve). The obese subjects had the device for 1 to 2 years and showed increased brain metabolism in brain regions associated with memory (hippocampus), reward and goal-directed behaviors (striatum), proprioception and motor function (cerebellum), and inhibitory control (orbitofrontal cortex). These increases in brain function in response to IGS paralleled decreases in “emotional eating” scores.

Interestingly, hippocampal activation has been reported in human brain imaging studies in response to food craving, hunger, taste, and food stimulation (Haase et al. 2009). In addition, the brain regions activated by IGS are activated in response to drug craving in drug-addicted subjects, which suggests that similar brain circuits may be involved in mediating food craving in obese individuals and drug craving in drug-addicted individuals (Volkow et al. 2011).

### Obesity and Gut Signaling

Few rodent in vivo neuroimaging studies focus on food presentation and its effects on brain activity, and only one study has assessed brain activation in response to food stimulus presentation in awake rats. In that study, the effects of leptin receptor deficiency, genetic obesity, and food restriction were tested on brain functional activation before and after olfactory stimulation with a bacon scent in obese leptin receptor–deficient (fa/fa) and control rats using µPET and [18F]FDG (Thanos et al. 2008b) (Figure 3). The obese rats showed lower metabolism in brain regions related to...
memory (hippocampus) and greater metabolism in brain areas associated with reward and goal-directed behavior (medial thalamus) relative to the control rats with normal leptin signaling.

This study was the first and to our knowledge only study to demonstrate the efficacy of using µPET for the noninvasive and repeated study of food cue effects in the brain of awake rats. Previous fMRI studies in obese rats involved delivery of the food stimuli via glucose infusion or ingestion directly into the stomach and were done under anesthesia (Chen et al. 2007). It was therefore not possible to assess the cognitive effects associated with exposure to food-related cues.

The findings from the experiments described here suggest that obesity may be a state of impaired food-related reward and memory function, and that gut peptides such as leptin may be involved in reward and memory-related processes specific for the acquisition of palatable food. A role for leptin in such processes has been implicated in human neuroimaging experiments. In particular, studies using fMRI showed unique functional activation of brain areas associated with reward, emotion, and inhibitory control in response to food cue presentation in leptin-deficient obese humans (Baicy et al. 2007; Farooqi et al. 2007).

Brain Imaging of Dopamine in Obese Subjects

Dopamine and Diet

The involvement of brain dopamine in obesity has been documented using [11C]raclopride in both human and animal studies. Findings from our group using this radioligand and PET have demonstrated decreased D2R binding availability in the striatum in morbidly obese humans (Wang et al. 2001) and rats (Thanos et al. 2008c) (Figure 4). Because PET allows for repeated measurements in the same subject over time, we were able to demonstrate that decreased D2R binding availability could be prevented when obese rats had limited access to food (Thanos et al. 2008c). This effect was also coupled to positive changes in body weight, locomotor activity, and circulating insulin and leptin levels (Thanos et al. 2008c). Furthermore, the same study showed that an overnight fast increased DA signaling in the striatum (measured indirectly via D2R binding availability at fasted and fed states).

More recently, in obese subjects, decreased D2R binding availability in the striatum was positively correlated to glucose metabolism in the dorsolateral prefrontal, medial orbitofrontal, anterior cingulate gyrus, and somatosensory cortices (Volkow et al. 2008). These frontal areas are involved in regulating inhibitory control and saliency attribution, suggesting that functional interactions between frontal and mesolimbic circuitry may act to regulate overeating. The positive correlation between glucose metabolism in the somatosensory regions and striatal D2R could also in part reflect DA regulation of the reinforcing or hedonic properties of food.

Another study from our group implicated psychosocial factors that may, in concert with imbalances in striatal DA metabolism, lead to impaired eating habits. This study showed that striatal DA responses in the dorsal striatum (measured as the change in D2R binding availability between a baseline and stimulus condition) were positively correlated with restraint behavior (the ability to consciously inhibit craving) during food presentation (Volkow et al. 2003). In the same study, emotionality was negatively correlated with baseline D2 receptor binding availability, suggesting that individuals with low availability may be prone to emotional disturbances and that, in the context of food availability, DA changes and emotional imbalances may inhibit the individual’s ability to refrain from consuming the food.

The ability to model such studies in animals using PET and combining behavioral monitoring with genetics may help elucidate some of the molecular determinants of such behaviors, which are currently not well understood.

Obesity and Bariatric Surgery

Because postsurgery patients show immediate and sustained decreases in food intake, and because striatal D1 receptors are decreased in obese humans and rodents (Thanos et al. 2008c; Wang et al. 2001), recent studies have focused on assessing D1R changes in response to bariatric surgery. Only two studies to date have documented such changes—and they reported opposite results.

Dunn and colleagues (2010) reported decreased D1R binding availability 7 weeks after surgery, whereas Steele and colleagues (2010) reported increases in D1R binding availability 6 weeks after surgery. Although both studies used similar surgical approaches and imaging procedures, they also reported results from a small cohort of patients...
Further research on DA system alterations in response to bariatric surgery is needed to clarify whether the decreased feeding observed in these patients is due to DA imbalances. In addition to this approach, and because this clinical population is not prevalent, preclinical bariatric surgery models can be used to obtain insight into the effects of such surgery on brain DA.

Conclusions

The use of functional imaging to map food-associated homeostatic and reward brain pathways in humans is arduous and time consuming because these pathways are densely clustered in higher cognitive areas (i.e., cortex). Furthermore, the reward or hedonic value associated with food is tied to memories, emotions, events, and specific individuals, making it difficult to assess the effects of food perception at the group level. Nevertheless, functional brain imaging studies have begun to shed light on the pathways associated with food and drug presentation and on the encoding of food and drug cues in the human brain. At the same time, new imaging techniques enable measurement of the rodent brain’s encoding of food and drug presentation.

Although these techniques are in their infancy, they hold significant promise for elucidating the networks and mechanisms involved in the brain’s encoding of food and drug reward and the cues that signal food or drugs. With rodent models, it is possible to manipulate experimental settings and variables (behavior, genetics, and diet) in efforts to enhance understanding and eventually treatment of drug addiction and compulsive overeating and obesity.

Acknowledgments

This work was supported by the National Institutes of Health National Institute on Alcohol Abuse and Alcoholism (AA11034, AA07574, AA07611) and the National Institute on Drug Abuse (NIDA; DA006278). The NIDA Postdoctoral Training Program at Mount Sinai School of Medicine also provided support (DA007135, Michaelides).
References


Downloaded from https://academic.oup.com/ilarjournal/article-abstract/53/1/59/656100 by guest on 16 March 2019


